|Description||The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL receptor. It seems to be more common in non-small cell lung cancer and it is still under Phase I|
|Synonyms||MGCD265 hydrochloride; MGCD-265 hydrochloride; MGCD 265 hydrochloride|
|Solubility||DMSO: ≥ 28 mg/mL|
|Application||The hydrochloride salt form of Glesatinib could be effectively targeting tumors that are driving to grow through MET and AXL receptor.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Mirati Therapeutics|
SU11274 is a selective Met tyrosine kinase inhibitor with IC50 of 10 nM.
NVP-BVU972 potently inhibits MET kinase but displays low inhibition against other kinases including the most closely related kinase RON with IC50 values of more...
PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor and is susceptible to oncogenic mutations (no activity to Y1230C mutant). It showed ...
Capmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with...
LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K(i)) of 2 nM, a pharmacodynamic residence time ...
Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
Tyrosine kinase inhibitor
It is a Tyrosine kinase inhibitor.
MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CEP-40783 is an orally-active, nanomolar potent and highly kinase-selective Type II inhibitor of the AXL and c-Met RTK with IC50 values of 7 nM and 12 nM, respe...
This active molecular is a c-MET and VEGFR inhibitor which is selective and specific in vitro. In vivo studies, TAS-115 suppressed the progression of MET-inacti...
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.
c-Met inhibitor 1
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic can...
golvatinib (also known as E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial ...
Altiratinib, also known as DCC-270, DP-5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer a...
AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...
SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...
LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity.
BMS-777607 is a novel prodrug of the dual Met/VEGFR-2 inhibitor.
AMG 337 is an orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-M...
The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL r...